Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDIH07)

Drug Name

1-methylcyclopropanecarboxylic acid Drug Info

Synonyms

1-Methylcyclopropane-1-carboxylic acid; 6914-76-7; 1-Methylcyclopropanecarboxylic acid; 1-Methyl-cyclopropanecarboxylic acid; Cyclopropanecarboxylic acid, 1-methyl-; DIZKLZKLNKQFGB-UHFFFAOYSA-N; Cyclopropanecarboxylicacid, 1-methyl-; 1-Methylcyclopropanecarboxylic acid, 98%; EINECS 230-020-7; PubChem16037; AC1Q5TAN; AC1Q2CXA; 1-methylcyclopropanoic acid; ACMC-209o6g; SCHEMBL113962; 1-Carboxy-1-methylcyclopropane; GTPL6500; DIZKLZKLNKQFGB-UHFFFAOYSA-; CTK2F4732; Methyl-cyclopropanecarboxylic acid; DTXSID50219201

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 81326
CAS Number: CAS 6914-76-7
TTD Drug ID: DMDIH07

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Free fatty acid receptor 2 (FFAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLPG0974	DMXO4T8	Abortion	JA00	Phase 2	[3]
HL-018	DMT3HKZ	Diabetic complication	5A2Y	Phase 1	[4]
(S)-4-CMTB	DMI12X9	Discovery agent	N.A.	Investigative	[5]
isobutyric acid	DMX4VY9	Discovery agent	N.A.	Investigative	[6]
pentanoic acid	DM56RAX	Discovery agent	N.A.	Investigative	[7]
trans-2-methylcrotonic acid	DMHJM0B	Discovery agent	N.A.	Investigative	[2]
AMG7703	DMJ6L9U	Discovery agent	N.A.	Investigative	[8]
PMID23589301C1	DMB7TE6	Discovery agent	N.A.	Investigative	[9]
CATPB	DMF7TBW	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Targeting Free fatty acid receptor 3 (FFAR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-4-CMTB	DMI12X9	Discovery agent	N.A.	Investigative	[10]
isobutyric acid	DMX4VY9	Discovery agent	N.A.	Investigative	[11]
pentanoic acid	DM56RAX	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 2 (FFAR2)	TT0FYAN	FFAR2_HUMAN	Agonist	[2]
Free fatty acid receptor 3 (FFAR3)	TTXDOHN	FFAR3_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6500).
2	Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40.
3	Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226).
5	Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209.
6	Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003 Jul 11;278(28):25481-9.
7	The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003 Mar 28;278(13):11312-9.
8	Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol. 2011 Jul;80(1):163-73.
9	Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. 2013 Jun 14;288(24):17296-312.
10	Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol. 2008 Dec;74(6):1599-609.
11	Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50.